Despite encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from PBMs. The insurers are often building barriers check here to reimbursement, such as steep expense criteria and PA that limit user opportunity. Industry believe that such reimbu